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A b s t r a c t
Background: Heart failure (HF) has become an epidemic. A similar situation is also observed for atrial fibrillation (AF). The 
CHA2DS2-VASc score is one of the most useful tools for thromboembolic risk assessment.
Aim: The aim of the study was to assess the prevalence of AF in patients with decompensated HF, who were divided into 
subgroups according to the CHA2DS2-VASc score.
Methods: We analysed the prevalence of AF in a group of 1108 patients (327 women) hospitalised due to HF decompensa-
tion in medical centres of different referral levels. Twenty-one patients refused to participate in the registry. The data were 
collected from Polish centres included in the European Society of Cardiology Heart Failure Long-Term Registry. The recruit-
ment period was from 2011 to 2014. The data were analysed retrospectively. Patients were divided into groups according to 
the CHA2DS2-VASC score.
Results: The study sample was characterised by a high occurrence of AF (44.3%), with the highest prevalence in patients with 
a CHA2DS2-VASC score ≥ 6 (61.3%, p = 0.01).
Conclusions: The CHA2DS2-VASc score may be a useful tool for detecting patients with HF characterised by the highest  
risk of AF.
Key words: atrial fibrillation, CHA2DS2-VASc, heart failure
Kardiol Pol 2019; 77, 3: 380–385
INTRODUCTION
The CHA2DS2-VASc score (congestive heart failure [HF], 
hypertension, age > 75 years, diabetes mellitus, history of 
stroke or thromboembolism, vascular disease, age 65 to 
74 years, female sex) is commonly used for thromboembolic 
risk stratification in patients with previously diagnosed atrial 
fibrillation (AF) [1, 2]. AF is a relatively frequent arrhythmia in 
elderly individuals, but also in patients with HF [1]. Thrombo-
embolic complications associated with AF are the main cause 
of disability and death among patients with HF [3–5]. Many 
HF patients without AF have high CHA2DS2-VASc scores [6] 
and are at high risk of thromboembolic complications despite 
the fact that AF is not confirmed [5]. 
We investigated patients with decompensated HF defined 
as a need for intravenous therapy with diuretics, inotropes, or 
vasodilators. Patients were hospitalised in Polish hospitals and 
were recruited to the European Society of Cardiology Heart 
Failure Long-Term Registry (ESC-HF-LT).
The aim of the study was to assess the prevalence of AF in 
patients with HF, who were divided into subgroups according 
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to the CHA2DS2-VASc score, and to evaluate the usefulness 
of this score for prediction of AF.
METHODS
All patients were enrolled in ESC-HF-LT, a prospective multi-
centre observational study conducted in Europe. The aim of 
the registry was to include many cardiac centres in order to 
accurately assess and show the real trends in the treatment 
of HF. The inclusion criterion was HF decompensation of any 
origin, and HF decompensation was defined as a need for 
intravenous therapy with inotropes, vasodilators, or diuretics.
We recruited patients with previously or newly diagnosed 
decompensated HF. The inclusion and exclusion criteria 
(age ≤ 18 years; lack of written informed consent) of our 
study were consistent with those of the registry. There were 
no other specific exclusion criteria. All the enrolled patients 
were included in the analyses. During the first phase of the 
registry (2011–2013), the enrolment was conducted on one 
day per week. This changed to five consecutive working days 
per trimester from October 2013 to September 2014 [7].
All patients were assessed using the CHA2DS2-VASc score, 
and the results were analysed with regards to the presence 
and type of AF. The diagnosis of AF was established on the 
basis of a current electrocardiogram (ECG) or available medical 
documentation (e.g. patients with sinus rhythm at presentation 
and with a history of AF confirmed by ECG).
In our study AF was classified according to the criteria of 
the European Society of Cardiology [1] as follows:
 — paroxysmal AF, when the episodes resolved spontane-
ously within seven days (mainly within 24 h) or resulted 
in cardioversion within this period;
 — persistent AF, when the episodes did not resolve sponta-
neously within seven days or required pharmacological 
and/or electrical cardioversion after seven days;
 — permanent AF, when it was present and accepted by the 
patient and doctor; no attempts to restore sinus rhythm 
were planned.
The analysis was cross-sectional and retrospective.
Statistical analysis
For the purpose of statistical analysis, Statistica 12.5 was used 
(StatSoft Inc., Tulsa, OK, USA). In the descriptive analysis, the 
categorical variables were described as a percentage, and the 
continuous variables, as a mean and standard deviation (SD). 
The c2 test was used to compare the categorical variables. For 
the continuous variables, the analysis of variance (ANOVA) or 
ANOVA on ranks was applied when the normality assumption 
was violated. The multivariate logistic regression was also used. 
A p-level < 0.05 was considered significant. 
RESULTS
Patient characteristics
A total of 1108 patients aged 65.6 ± 13.5 years (327 women, 
781 men) were enrolled in the study. Twenty-one patients 
refused to participate in the study and were not considered 
for analyses. The investigated patients were over 18 years of 
age and were hospitalised due to decompensated HF in Polish 
medical centres of different referral levels. 
Of the total population, 34% had left ventricular ejection 
fraction (LVEF) < 30%, 49.7% had LVEF between 30% and 
50%, and 16.3% had LVEF > 50%. New York Heart Associa-
tion (NYHA) functional class IV was reported in 22.7% of pa-
tients; class III, in 38.6%; class II, 34.3%; and class I, in 4.2%. 
Hypertension was noted in 63.2% of the population, while 
32.5% of patients had diabetes, 23.7% had chronic kidney 
disease, and 57% were cigarette smokers. Previous stroke 
or transient ischaemic attack occurred in 11.3% of patients.
Decompensated HF of ischaemic origin was predominant 
in the analysed group (51.4%); other aetiologies included dila-
tive cardiomyopathy (22.7%), valvular heart disease (11.1%), 
hypertension (6.1%), and tachyarrhythmia-induced cardio-
myopathy (2.5%). Other causes constituted 4.1%. 
Association of clinical features  
with the CHA2DS2-VASc score
The comparison of clinical variables between patients clas-
sified according to the CHA2DS2-VASc score is presented in 
Tables 1A and 1B. The comparison of the variables between 
patients with a CHA2DS2-VASc score of 0–5 and ≥ 6 in 
the whole population and according to sex is presented in 
Tables 2A and 2B.
In our study, AF was present in 44.3% of patients. An 
increase in the CHA2DS2-VASc score was non-linear — we 
observed a significant increase in the prevalence of AF when 
the score was ≥ 6 in the whole population and in women 
(Table 2B). Differences in the CHA2DS2-VASc score were as-
sociated with the age of patients and serum creatinine levels 
in women (p = 0.006). We also observed lower serum cho-
lesterol levels and lower body mass in women (p < 0.001). 
The increase in the CHA2DS2-VASc score was correlated with 
an increase in LVEF in the whole population (p < 0.001) and 
a decrease in N-terminal pro–B-type natriuretic peptide in 
women (p = 0.009).
In the multivariate logistic regression analysis, AF was 
independently correlated with a history of HF (odds ratio [OR] 
3.55, 95% confidence interval [CI] 2.03–6.21; p = 0.004; 
for HF with previous hospitalisation), age (OR 1.035, 95% CI 
1.022–1.048; p < 0.001), previous stroke (OR 1.613, 95% 
CI 1.046–2.487; p = 0.03), and female sex (OR 0.68, 95% 
CI 0.477–0.969; p = 0.03).
DISCUSSION
We investigated patients with ischaemic HF and non-ischae-
mic cardiomyopathy, who were admitted due to HF decom-
pensation. We assessed all patients using the CHA2DS2-VASc 
score, previously designed for AF. Our patients were character-
ised by a high rate of AF (44.3%), which was higher than in the 
general population (2%) [8], and also higher compared with 
www.kardiologiapolska.pl









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHA2DS2-VASc and atrial fibrillation in heart failure
383
the study of Zafrir et al. [9], who reported the results for the 
whole group of ESC-HF-LT patients (outpatients were 
also enrolled). The prevalence of AF was 27% in HF with 
reduced ejection fraction [EF], 29% in HF with moder-
ately reduced EF, and 39% in HF with preserved EF [9]. The 
discrepancy between our study and the study of Zafrir et al. [9] 
can be explained by the differences in the study population 
(decompensated HF vs. the whole group of patients with 
HF). In the subgroup of patients with decompensated HF, 
the results were similar to our findings (43%, 34%, and 31%, 
respectively). Our results are consistent with findings of other 
cross-sectional studies on patients with decompensated HF 
[10–15].
More frequent coexistence of both diseases (HF and AF) 
can be explained by similar pathophysiological mechanisms 
and the causative relationship between these two entities.
The available literature data show that the CHA2DS2-VASc 
score may be useful for the assessment of mortality risk in 
patients with HF, irrespective of AF [16]. These observations 
are in line with the results of the present study. An increase 
in the CHA2DS2-VASc score is associated with a more severe 
condition of patients. Factors such as older age and higher 
creatinine levels have an adverse effect on the prognosis in 
HF [17]. Interestingly, patients with higher scores had lower 
body weight and lower cholesterol levels, which can be 
partly explained by frailty and possibly by therapeutic inter-
ventions. Patients with lower scores also had shorter height 
(data not shown). However, other reports on patients with AF 
demonstrated that being taller was a risk factor for AF [18].
Another interesting observation is related to the rela-
tionship between LVEF and the CHA2DS2-VASc score. An 
increase in the score was associated with  higher LVEF. It 
can be partially explained by the fact that patients above 
the age of 70 years hospitalised due to decompensated 
HF have preserved LVEF (40% to 55%) [19]. Similar results 
related to LVEF were also observed in a Brazilian registry 
[14]. Patients hospitalised due to decompensated HF ac-
companied by AF were characterised by higher LVEF than 
other patients. Similarly, the rate of AF was lower than ex-
pected in the TSOC-HFrEF registry including patients with 
decompensated HF and reduced LVEF [20].
Other authors also showed that some clinical factors 
included in the CHA2DS2-VASc score, such as diabetes, hyper-
tension, congestive HF, or age, were also predictors of AF [21]. 
They also showed that male sex increased the risk of AF [21].
Our study confirmed that patients with a score ≥ 6 had 
a higher prevalence of AF, which occurred in 61.3% of patients 
in this subgroup. However, this relationship was non-linear 
in patients with lower scores (< 6), and these patients had 
similar occurrence of AF. Our observations are in line with 
other studies. Melgaard et al. [22] classified patients with 
HF according to the presence of AF. They observed that the 
risk of thromboembolic complications was higher in patients 
with a CHA2DS2-VASc score ≥ 4 without confirmed AF than 
in patients with confirmed AF. This is probably explained by 
a high rate of silent paroxysmal AF in patients with high scores 
and a beneficial role of anticoagulant therapy. 
Our study was based on the data obtained from a pro-
spective observational registry. The registry was based on 
voluntary participation of patients, and not all medical centres 
participated in the ESC-HF-LT. However, the registry data 
were of high quality because they were continuously moni-
tored automatically and manually to avoid any inaccuracy or 
inconsistency. Furthermore, we do not have long-term ECG 
monitoring of patients, and some asymptomatic AF episodes 
might have been overlooked and the real incidence of AF 
may be even higher than the one presented.
To conclude, the CHA2DS2-VASc score ≥ 6 in patients hos-
pitalised due to decompensated HF is related to AF in > 60% 
of patients. However, higher scores are associated with AF 
in a non-linear manner. Active monitoring for AF in patients 
with very high CHA2DS2-VASc scores who are hospitalised 
due to HF decompensation seems useful and reasonable. 
These encouraging results may lead to the development of 
a new score for the prediction of AF, comprising risk factors 
for AF. A step in this direction has been made by neurologists, 
who recommended active screening for AF in patients after 
ischaemic stroke. It was demonstrated that AF may be con-
firmed by 30-day ECG monitoring in almost 11% of patients 
with ischaemic stroke [23].
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WHAT IS NEW?
The CHA2DS2-VASc score is commonly used for thromboembolic risk stratification in patients with previously diagnosed 
atrial fibrillation (AF). Many patients without AF have high CHA2DS2-VASc scores. Our observations demonstrated that 
the CHA2DS2-VASc score ≥ 6 in patients hospitalised due to decompensated heart failure is related to AF in > 60% of 
patients. Active screening for AF in patients with very high scores who are hospitalised due to heart failure decompensation 
seems useful.
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